K2VC (Chinese: 险峰), founded in 2010 by Chen Keyi and Bao Fan, is an early-stage venture capital firm headquartered in Beijing, China. See contact routes.
K2VC (Chinese: 险峰), founded in 2010 by Chen Keyi and Bao Fan, is an early-stage venture capital firm headquartered in Beijing, China, that manages both RMB and USD funds with approximately 10 billion RMB in assets under management. The firm’s investment thesis targets technology advancement, industrial upgrades, business model innovation, and consumer lifestyle revolution, with dedicated platforms including K2 Angel Partners for TMT and advanced manufacturing, and K2 Bio Partners for life sciences and healthcare. K2VC typically invests at the angel to early-stage levels, focusing on sectors such as artificial intelligence, biotechnology, fintech, new energy, SaaS, and robotics across China. While specific check sizes and lead/follow behavior are not publicly detailed, the firm has invested in over 700 companies, indicating a high-volume, early-stage strategy. Notable portfolio companies include ProfoundBio, which K2VC led in a Series Pre-A round in 2020 and was later acquired by Genmab for $1.8 billion in 2024, as well as investments in TMT and biotech startups through its two main arms. The firm’s name “K2” references the world’s second-highest
Details on this firm come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Beijing.
Investors like K2vc · Full investor directory · Investor access · Company funding database